Skip to main content

Advertisement

Log in

The influence of anti-VEGF therapy on present day management of macular edema due to BRVO and CRVO: a longitudinal analysis on visual function, injection time interval and complications

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

An Erratum to this article was published on 10 October 2014

Abstract

The purpose of this study was to evaluate the impact of intravitreal bevacizumab injections on the management and outcome of patients affected by retinal vein occlusions, their effectiveness on morphological and functional parameters, the modalities of long-term management and the need for additional laser treatment due to ischemic retinal evolution. Patients diagnosed with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) had a comprehensive work-up including complete ophthalmic examination, fluorangiography (FA), optical coherence tomography (OCT), visual field testing (VFT), microperimetry (MP), and laser flare photometry (LFP). In case of BRVO, intraocular bevacizumab injection was performed if significant macular edema/visual deficit was still present 3 months after onset of occlusion and injections were started at presentation in case of CRVO. Post-injection follow-up examination including best corrected visual acuity (BCVA), intraocular pressure (IOP), LFP, OCT, MP, and VFT were performed monthly and recorded at the end of follow-up. Follow-up FA was performed between 12 and 18 months after diagnosis. Injections were repeated in case of recurrence of a significant central macular edema. Patients were subdivided into 2 groups according to number of injections: 1–4 injections or more than 4 injections. The proportion of resolved cases (no recurrence after a minimum follow-up of 12 months) was calculated and correlated with number of injections. In patients needing sustained injections, management modalities were recorded. The proportion of patients having needed laser photocoagulation treatment because of significant ischemic signs was recorded. Fifty-one patients were diagnosed with retinal vein occlusion between 2006 and 2012 at the Centre for Specialized Ophthalmic Care (COS) in Lausanne, Switzerland. Forty-four had enough data and were included in the study. Nine eyes were affected by CRVO and 35 were affected by BRVO. Mean BCVA at presentation was 0.24 ± 0.2 and improved to 0.81 ± 0.38 (p < 0.01) at 48 months. MP improved from 184.9 ± 92 to 362.5 ± 56.2 (p < 0.01) at 42 months follow-up. The number of injections varied from 1 to 25 (mean 5.5 ± 5.43). 31/44 eyes received 1–4 injections (group 1) of which all were recurrence free, with a follow-up of at least 1 years in all. 13/44 eyes received more than 5 injections (group 2) with functional and morphological parameters maintained in 9/13 but only 1/13 patients showed resolution. Rhythm of injection varied from one patient to another but 8/13 patients needing continuous injections had a constant time interval between injections. In 8/44 patients, laser photocoagulation had to be performed due to ischemic complications. The visual outcome using bevacizumab intravitreal injection was exceptionally good and functional parameters such as BCVA, MP, and VFT improved significantly. In about two-thirds of patients, resolution was obtained after 1–4 injections. In one-third of patients, continuous injections were necessary but a constant rhythm for re-injection for each patient could be established allowing to reduce to a minimum follow-up visits. The absence of significant side effects allowed to re-treat apparently without limitation achieving maintained visual function. FA monitoring for the detection of ischemic complications should not be neglected especially in cases where bevacizumab could be discontinued.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Yau JW, Lee P, Wong TY, Best J, Jenkins A (2008) Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J. 38(12):904–910

    Article  CAS  PubMed  Google Scholar 

  2. Royal College of Ophthalmologists. Retinal vein occlusion guidelines. Royal College of Ophthalmologists Web site. http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf. Accessed 30 July 2009

  3. Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98:133–141

    CAS  PubMed Central  PubMed  Google Scholar 

  4. The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271–282

    Article  Google Scholar 

  5. The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491

    Article  Google Scholar 

  6. Finkelstein D (1996) Laser therapy for central retinal vein obstruction. Curr Opin Ophthalmol 7(3):80–83

    Article  CAS  PubMed  Google Scholar 

  7. Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ (2001) Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina 21(5):408–415

    Article  CAS  PubMed  Google Scholar 

  8. Chung EJ, Lee H, Koh HJ (2008) Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246(7):967–974

    Article  CAS  PubMed  Google Scholar 

  9. Weiss JN, Bynoe LA (2001) Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 108(12):2249–2257

    Article  CAS  PubMed  Google Scholar 

  10. Schumann M, Hansen LL, Janknecht P, Witschel H (1993) Isovolemic hemodilution in central retinal vein occlusion in patients less than 50 years of age. Klin Monbl Augenheilkd 203(5):341–346

    Article  CAS  PubMed  Google Scholar 

  11. Parodi MB (2004) Medical treatment of retinal vein occlusions. Semin Ophthalmol 19(1–2):43–48

    Article  PubMed  Google Scholar 

  12. Asano S, Miyake K, Miyake S, Ota I (2007) Relationship between blood-aqueous barrier disruption and ischemic macular edema in patients with branch or central retinal vein occlusion: effects of sub-tenon triamcinolone acetonide injection. J Ocul Pharmacol Ther 23(6):577–584

    Article  CAS  PubMed  Google Scholar 

  13. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E (2002) Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 86(2):247–248

    Article  PubMed Central  PubMed  Google Scholar 

  14. Ip MS, Kumar KS (2002) Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol 120(9):1217–1219

    PubMed  Google Scholar 

  15. Jonas JB, Kreissig I, Degenring RF (2002) Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240(9):782–783

    Article  PubMed  Google Scholar 

  16. Kaiser PK (2005) Steroids for branch retinal vein occlusion. Am J Ophthalmol 139(6):1095–1096

    Article  CAS  PubMed  Google Scholar 

  17. Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, Baath J, Buys YM (2013) Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol 58(4):291–310

    Article  PubMed  Google Scholar 

  18. Carnahan MC, Goldstein DA (2000) Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 11(6):478–483

    Article  CAS  PubMed  Google Scholar 

  19. Thompson JT (2006) Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 141(4):629–637

    Article  CAS  PubMed  Google Scholar 

  20. Stahl A, Agostini H, Hansen LL, Feltgen N (2007) Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245(10):1429–1436

    Article  CAS  PubMed  Google Scholar 

  21. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ (2008) Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246(1):81–87

    Article  CAS  PubMed  Google Scholar 

  22. Hayreh SS (1983) Classification of central retinal vein occlusion. Ophthalmology 90(5):458–474

    Article  CAS  PubMed  Google Scholar 

  23. Glacet-Bernard A, Mahdavi KN, Coscas G, Zourdani A, Fardeau C (1994) Macular grid photocoagulation in persistent macular edema due to central retinal vein occlusion. Eur J Ophthalmol. 4(3):166–174

    CAS  PubMed  Google Scholar 

  24. Parodi MB, Di Stefano G, Ravalico G (2008) Grid laser treatment for exudative retinal detachment secondary to ischemic branch retinal vein occlusion. Retina 28(1):97–102

    Article  PubMed  Google Scholar 

  25. McIntosh RL, Mohamed Q, Saw SM, Wong TY (2007) Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114(5):835–854 Epub 2007 Mar 30

    Article  PubMed  Google Scholar 

  26. Ohashi H, Oh H, Nishiwaki H, Nonaka A, Takagi H (2004) Delayed absorption of macular edema accompanying serous retinal detachment after grid laser treatment in patients with branch retinal vein occlusion. Ophthalmology 111(11):2050–2056

    Article  PubMed  Google Scholar 

  27. Mohamed Q, McIntosh RL, Saw SM, Wong TY (2007) Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 114(3):507-19, 524

  28. The Central Vein Occlusion Study Group (1995) Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group M report. Ophthalmology 102:1425–1433

    Article  Google Scholar 

  29. Russo V, Barone A, Conte E, Prascina F, Stella A et al. (2009) Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina (Phila, Pa) 29: 511–515

  30. Smith GC, Pell JP (2003) Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 327(7429):1459–1461

    Article  PubMed Central  PubMed  Google Scholar 

  31. Mitry D, Bunce C, Charteris D (2013) Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 31:1

    Google Scholar 

  32. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594–1602

    Article  PubMed  Google Scholar 

  33. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G et al (2012) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 7:e42701

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L (2014) Patel A; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN Study. Ophthalmology 121(1):209–219

    Article  PubMed  Google Scholar 

  35. Epstein DL, Algvere PV, Von Wendt G, Seregard S, Kvanta A (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 119:2587–2591

    Article  PubMed  Google Scholar 

  36. Gokce G, Sobaci G, Durukan AH, Erdurman FC (2013) Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion. Postgrad Med 125(5):51–58

    Article  PubMed  Google Scholar 

  37. Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V, Menezo V, Shao E, Taylor SR (2013) Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol 97(8):1040–1044

    Article  PubMed  Google Scholar 

  38. Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U (2012) Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results. Retina 32(8):1471–1479

    Article  CAS  PubMed  Google Scholar 

  39. Yuan A, Ahmad BU, Xu D, Singh RP, Kaiser PK, Martin DF, Sears JE, Schachat AP, Ehlers JP (2014) Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Int J Ophthalmol 7(1):86–91

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marina Papadia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Papadia, M., Misteli, M., Jeannin, B. et al. The influence of anti-VEGF therapy on present day management of macular edema due to BRVO and CRVO: a longitudinal analysis on visual function, injection time interval and complications. Int Ophthalmol 34, 1193–1201 (2014). https://doi.org/10.1007/s10792-014-0002-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-014-0002-1

Keywords

Navigation